Literature DB >> 14555525

Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines.

Susan K Lutgendorf1, Steven Cole, Erin Costanzo, Sarah Bradley, Jeremy Coffin, Sarvenaz Jabbari, Kaitlin Rainwater, Justine M Ritchie, Maria Yang, Anil K Sood.   

Abstract

PURPOSE: Stress has long been believed to influence carcinogenesis, but little is known about physiological mechanisms that may underlie these effects. We have recently observed lower levels of vascular endothelial growth factor (VEGF) in ovarian cancer patients with greater social support, whereas higher VEGF was found in patients with greater distress. The goal of this study was to examine possible mechanisms underlying these relationships. EXPERIMENTAL
DESIGN: The effects of stress-related mediators including norepinephrine (NE), epinephrine, isoproterenol (a nonspecific beta-adrenergic agonist), and cortisol on the production of VEGF by the ovarian cell lines SKOV3 and EG were investigated.
RESULTS: NE and isoproterenol significantly enhanced VEGF production by SKOV3 cells, and all three of the adrenergic agonists enhanced VEGF production by EG cells. These effects were blocked by the beta antagonist propranolol, supporting a role for beta-adrenergic receptors in these effects. Reverse transcriptase-PCR studies indicated constitutive expression of beta-1 and beta-2 adrenergic receptors on both cell lines. Effects of cortisol on VEGF production varied according to the specific cell line and dose, with stimulating effects on SKOV3 at pharmacologic doses (1000 nM) and on EG at physiological stress level doses (10 nM), and inhibitory effects on EG at pharmacologic doses. Although priming with cortisol blunted NE-induced VEGF production from both cell lines at 3 h, significant increases in VEGF were still seen. Priming with cortisol enhanced isoproterenol-induced VEGF production from SKOV3.
CONCLUSION: These findings provide the first experimental evidence of a pathway by which biobehavioral stress mediators could directly contribute to the progression of ovarian tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14555525

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  128 in total

1.  β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study.

Authors:  Stanley Lemeshow; Henrik Toft Sørensen; Gary Phillips; Eric V Yang; Sussie Antonsen; Anders H Riis; Gregory B Lesinski; Rebecca Jackson; Ronald Glaser
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-20       Impact factor: 4.254

Review 2.  Infantile hemangioma-mechanism(s) of drug action on a vascular tumor.

Authors:  Shoshana Greenberger; Joyce Bischoff
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

Review 3.  Biobehavioral factors and cancer progression: physiological pathways and mechanisms.

Authors:  Susan K Lutgendorf; Anil K Sood
Journal:  Psychosom Med       Date:  2011-10-21       Impact factor: 4.312

Review 4.  Neuroendocrine influences on cancer progression.

Authors:  Guillermo N Armaiz-Pena; Steve W Cole; Susan K Lutgendorf; Anil K Sood
Journal:  Brain Behav Immun       Date:  2012-06-21       Impact factor: 7.217

Review 5.  Host factors and cancer progression: biobehavioral signaling pathways and interventions.

Authors:  Susan K Lutgendorf; Anil K Sood; Michael H Antoni
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

6.  Role for catecholamines in tumor progression: possible use for β-blockers in the treatment of cancer.

Authors:  Eric V Yang
Journal:  Cancer Biol Ther       Date:  2010-07-06       Impact factor: 4.742

7.  A comparison of the effects of epidural analgesia versus traditional pain management on outcomes after gastric cancer resection: a population-based study.

Authors:  Kenneth C Cummings; Meatal Patel; Phyo Than Htoo; Paul M Bakaki; Linda C Cummings; Siran Koroukian
Journal:  Reg Anesth Pain Med       Date:  2014 May-Jun       Impact factor: 6.288

8.  hTERT mediates norepinephrine-induced Slug expression and ovarian cancer aggressiveness.

Authors:  M J Choi; K H Cho; S Lee; Y J Bae; K J Jeong; S Y Rha; E J Choi; J H Park; J M Kim; J-S Lee; G B Mills; H Y Lee
Journal:  Oncogene       Date:  2014-08-25       Impact factor: 9.867

9.  Impact of cardiovascular comorbidity on ovarian cancer mortality.

Authors:  Eileen H Shinn; Daniel J Lenihan; Diana L Urbauer; Karen M Basen-Engquist; Alan Valentine; Laura Palmero; Myrshia L Woods; Pooja Patel; Alpa M Nick; Mian M K Shahzad; Rebecca L Stone; Antoinette Golden; Emma Atkinson; Susan K Lutgendorf; Anil K Sood
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-17       Impact factor: 4.254

10.  VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine.

Authors:  Eric V Yang; Elise L Donovan; Don M Benson; Ronald Glaser
Journal:  Brain Behav Immun       Date:  2007-11-05       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.